The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?

English version České info

Ameet Sarpatwari and Aaron Kesselheim explore whether stripping branded drugs of trademark protection would improve the efficiency and fairness of health care.

Vyšlo v časopise: The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?. PLoS Med 13(2): e32767. doi:10.1371/journal.pmed.1001955
Kategorie: Essay
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001955

Souhrn

Ameet Sarpatwari and Aaron Kesselheim explore whether stripping branded drugs of trademark protection would improve the efficiency and fairness of health care.

Zdroje

1. Pew Charitable Trusts (2013). Persuading the prescribers: pharmaceutical industry marketing and its influence on physicians and patients. http://www.pewtrusts.org/en/research-and-analysis/fact-sheets/2013/11/11/persuading-the-prescribers-pharmaceutical-industry-marketing-and-its-influence-on-physicians-and-patients. Accessed 26 August 2015.

2. U.S.C. § 1052(e)(5).

3. Traffix Devices, Inc. v. Marketing Displays, Inc., 532 U.S. 23 (2001).

4. CTMR, 2009 O.J. (L78) 1, Art. 7.

5. Kesselheim AS, Misono AS, Shrank WH, Greene JA, Doherty M, Avorn J, et al. (2015). Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med 173:202–208.

6. Kesselheim AS, Bykov K, Avorn J, Tong A, Doherty M, Choudhry NK (2014). Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med 161:96–103. doi: 10.7326/M13-2381 25023248

7. Greene JA. Generic: the unbranding of modern medicine. Baltimore: Johns Hopkins University Press; 2014.

8. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, et al (2008). Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 300:2514–2526. doi: 10.1001/jama.2008.758 19050195

9. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, et al (2010). Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 70:605–621. doi: 10.2165/10898530-000000000-00000 20329806

10. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, et al (2006). The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 166:332–337. 16476874

11. Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, et al. (2014). Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med 161:400–407. doi: 10.7326/M13-2942 25222387

12. Hochman M, Hochman S, Bor D, McCormick D (2008). News media coverage of medication research: reporting pharmaceutical company funding and use of generic medication names. JAMA 300:1544–1550. doi: 10.1001/jama.300.13.1544 18827211

13. Ryskina KL, Dine CJ, Kim EJ, Bishop TF, Epstein AJ (2015). Effect of attending practice style on generic medication prescribing by residents in the clinic setting: an observational study. J Gen Intern Med 30:1286–1293. doi: 10.1007/s11606-015-3323-5 26173522

14. Steinman MA, Chren MM, Landefeld CS (2007). What's in a name? Use of brand versus generic drug names in United States outpatient practice. J Gen Intern Med 22:645–648. 17443372

15. Kwo EC, Kamat P, Steinman MA (2009). Physician use of brand versus generic drug names in 1993–1994 and 2003–2004. Ann Pharmacother 43:459–468. doi: 10.1345/aph.1L502 19261956

16. Chu C, Rudant E, Bonvalet M, Agostini H, Cavalie P, Bonhomme-Faivre L, et al. (2011). Generic drug prescriptions following hospital discharge: a prospective study in France. Eur J Intern Med. 22:e45–e49. doi: 10.1016/j.ejim.2011.01.016 21925042

17. OECD (2013). Pharmaceutical generic market share. http://www.oecd-ilibrary.org/docserver/download/8113161ec042.pdf?expires=1449685241&id=id&accname=guest&checksum=2443C42C90A67824401DB0506E998806. Accessed 9 December 2015.

18. IMS Health (2010). Generic medicines: essential contributors to the long-term health of society. http://www.imshealth.com/imshealth/Global/Content/Document/Market_Measurement_TL/Generic_Medicines_GA.pdf. Accessed 30 August 2015.

19. Shrank WH, Choudhry NK, Agnew-Blais J, Federman AD, Liberman JN, Liu J, et al. (2010). State generic substitution laws can lower drug outlays under Medicaid. Health Aff 29:1383–1390.

20. Shrank WH, Liberman JN, Fischer MA, Avorn J, Kilabuk E, et al (2011). The consequences of requesting "dispense as written". Am J Med 124:309–317. doi: 10.1016/j.amjmed.2010.11.020 21435421

21. IMS Institute for Healthcare Informatics (2013). Avoidable costs in U.S. health care. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Institute/RUOM-2013/IHII_Responsible_Use_Medicines_2013.pdf. Accessed 30 August 2015.

22. Bronnenberg BJ, Dubé JP, Gentzkow M, Shapiro JS. Do pharmacists buy Bayer? Informed shoppers and the brand premium (2015). Quart J Econ 130:1669–1726.

23. Engelberg AB. Have prescription drug brand names become generic? (2014). Am Journal Manag Care 20:867–869.

24. Ross J, Kesselheim AS. Prescription-drug coupons—no such thing as a free lunch (2013). New Eng J Med 369:1188–1189. doi: 10.1056/NEJMp1301993 23984672